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The prevalence and cost of diabetes is growing rapidly 
worldwide (1). People with diabetes are twice as likely to be 
admitted to the hospital, and at least 10% of those in the 
hospital have diabetes at any one time (2). In some locations 
and age groups, it is as many as one in five (3). The associ-
ated costs of excess admissions, as well as increased costs 
per admission, are significant contributors to the financial 
burden borne by healthcare systems from diabetes and often 
reflect preventable morbidity suffered by patients (4).
As one of the most dominant risk factors, dyslipidemia 
has been found to be associated with coronary heart dis-
ease (CHD) among people with T2D in large prospec-
tive studies such as the UK Prospective Diabetes Study 
(UKPDS) (1, 2). Both total and LDL cholesterol have been 
found to correlate with risk of CHD consistently over differ-
ent studies (5). Among various lipid profile measurements, 
the total cholesterol to HDL cholesterol ratio (TC/HDL) 
has been widely used as a prognostic factor to predict the 
risk of CVD both in general (3) and diabetes populations, 
as applied in the UKPDS score, reflecting its association 
both with CHD (4) and stroke in people with T2D.
Abstract Total cholesterol to HDL cholesterol ratio (TC/
HDL) is an important prognostic factor for CVD. This study 
used restricted cubic spline modeling to investigate the dose-
response associations between TC/HDL and both CVD hospi-
talization and CVD rehospitalization in two independent 
prospective cohorts. The East Cambridgeshire and Fenland 
cohort includes 4,704 patients with T2D from 18 general prac-
tices in Cambridgeshire. The Randomized controlled trial of 
Peer Support In type 2 Diabetes cohort comprises 1,121 pa-
tients with T2D with posttrial follow-up data. TC/HDL and 
other demographic and clinical measurements were measured 
at baseline. Outcomes were CVD hospitalization over 2 years 
and CVD rehospitalization after 90 days of the prior CVD hos-
pitalization. Modeling showed nonlinear relationships be-
tween TC/HDL and risks of CVD hospitalization and 
rehospitalization consistently in both cohorts (all P < 0.001 for 
linear tests).  The lowest risks of CVD hospitalization and 
rehospitalization were consistently found for TC/HDL at 2.8 
(95% CI: 2.6–3.0) in both cohorts and both overall and by 
gender. This is lower than the current lipid control target, 4.0 
of TC/HDL. Reducing the TC/HDL target to 2.8 would 
include a further 33–44% patients with TC/HDL in the 2.8–4.0 
range. Studies are required to assess the effectiveness and 
cost-effectiveness of the earlier introduction of, and more in-
tensive, lipid-lowering treatment needed to achieve this new 
lower TC/HDL target.—Yu, D., Y. Cai, R. Qin, J. Graffy, 
D. Holman, Z. Zhao, and D. Simmons. Total/high density 
lipoprotein cholesterol and cardiovascular disease (re)hos-
pitalization nadir in type 2 diabetes. J. Lipid Res. 2018. 59: 
1745–1750.
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CVD฀hospitalization฀and฀rehospitalization฀are฀important฀
components of the increased costs of diabetes and the pre-
ventable morbidity suffered by people with diabetes (4). 
The TC/HDL management target among those with dia-
betes฀ is฀ an฀ important฀ risk฀ factor฀ for฀CVD฀hospitalization฀
and฀rehospitalization฀and฀might฀be฀useful฀in฀deining฀pop-
ulation risk of morbidity and increased health costs (6). 
Few studies have set out to investigate the associations be-
tween฀TC/HDL฀level฀and฀risk฀of฀CVD฀hospitalization฀and฀
rehospitalization฀in฀people฀with฀T2D.
In฀our฀previous฀risk฀score฀to฀predict฀CVD฀hospitalization฀
and฀rehospitalization,฀TC฀and฀HDL฀were฀ incorporated฀as฀
four separated polynomial fractional terms to achieve a bet-
ter model discrimination and calibration, which did not 
allow further examination of the association between the 
TC/HDL฀ratio฀and฀the฀risks฀of฀CVD฀hospitalization฀and฀re-
hospitalization฀(7).฀For฀example,฀ it฀ is฀unclear฀whether฀or฀
not there is a dose-response relationship between TC/HDL 
and฀the฀risk฀of฀hospitalization฀in฀people฀with฀T2D฀and,฀if฀so,฀
whether this is linear. If there is a nonlinear relationship, 
and a potential threshold exists between TC/HDL and 
CVD฀ hospitalization,฀ it฀ could฀ inform฀ lipid฀ management฀
among people with T2D in the primary care setting, thereby 
reducing฀hospitalization฀and฀health฀payments.
The aim of this study was to investigate the dose-response 
relationships between TC/HDL and risks of CVD hospital-
ization฀over฀the฀subsequent฀2฀years,฀and฀CVD฀rehospitaliza-
tion up to 90 days, following a prior CVD-related hospital 
stay in two independent prospective cohort studies.
METHODS
Data source and study population
ECF cohort.฀ In฀the฀East฀Cambridgeshire฀and฀Fenland฀(ECF)฀co-
hort, patient lists from 18 general practices across Cambridgeshire, 
England,฀in฀2008/2009฀were฀collated฀and฀linked฀with฀hospital฀ad-
missions (Secondary Uses Service) data as part of an evaluation of 
diabetes care across the county by the local health board, the Na-
tional Health Service (NHS) Cambridgeshire. This cohort was lim-
ited฀to฀volunteer฀practices฀using฀the฀Egton฀Medical฀Information฀
Systems฀(EMIS)฀general฀practitioner฀(GP)฀software฀system,฀from฀
which a predefined set of data could be extracted. There was no 
systematic selection process for these surgeries, and data extracted 
were for their entire diabetes population. T2D was defined based 
on GP diagnosis (8). All patients with diabetes had follow-up hos-
pitalization฀data฀ to฀2010–2011.฀Hospital฀admissions฀ to฀NHS฀and฀
private hospitals within and outside Cambridgeshire were followed 
up. No personal identifiers were released to researchers, and all 
subsequent฀analyses฀were฀conducted฀on฀anonymized฀datasets.
RAPSID cohort.฀ The฀design฀and฀methods฀of฀the฀Randomized฀
controlled trial of Peer Support In type 2 Diabetes (RAPSID) trial 
have been published previously (6), as have its CONSORT (Con-
solidated Standards of Reporting Trials) diagram and the results 
of its primary outcomes (9). Briefly, RAPSID was a 2 × 2 factorial 
cluster฀ randomized฀ controlled฀ trial฀ comparing฀ four฀ groups:฀ 
controls, 1:1 (individual) peer support, group peer support, 
and combined 1:1 and group peer support among patients with 
T2D. Participants had their diabetes for at least 12 months, 
and those with dementia or psychotic illness were excluded. T2D 
was defined based on GP diagnosis. Participants were recruited 
from communities across Cambridgeshire and neighboring areas 
of฀Essex฀and฀Hertfordshire.฀Follow-up฀data฀were฀only฀available฀ 
for participants in Cambridgeshire and neighboring areas of 
Hertfordshire that are served by the Cambridgeshire and Peter-
borough Clinical Commissioning Group (CCG). Clusters were 
defined by local government (“parish council”) boundaries. The 
intervention was developed following a pilot (10), using a frame-
work defined by Peers for Progress (11). Peers facilitating peer 
support were termed peer support facilitators, and their selection, 
training, and support and the overall program are described else-
where฀(12).฀The฀intervention฀lasted฀8–12฀months฀and฀was฀com-
menced and concluded, cluster by cluster, between 02/06/11 and 
12/04/12.
At baseline, demographic data, blood pressure, and hemoglo-
bin฀A1c฀(HbA1c)฀and฀lipid฀proile฀were฀collected.฀Each฀participant฀
was฀followed฀up฀until฀June฀2015฀(0.91–4.07฀years฀follow-up฀from฀
beginning/entry฀ into฀ the฀ trial).฀Hospitalization฀ (NHS฀hospitals฀
and฀private฀hospitals),฀Accident฀and฀Emergency,฀and฀outpatient฀
visits within/outside Cambridgeshire and the included areas of 
Hertfordshire were completely collected through Cambridgeshire 
and Peterborough CCG (13), including the elective/nonelective 
status and International Classification of Diseases 10 (ICD-10) 
codes (8).
Defining CVD hospitalization and rehospitalization
The primary outcome of the study was having at least one hos-
pitalization฀with฀CVD฀as฀the฀primary฀diagnosis฀(ICD-10:฀I20–I25,฀
I60–I69,฀and฀I73฀in฀the฀irst฀ICD฀ield)฀over฀the฀2-year฀follow-up฀
and฀ having฀ at฀ least฀ one฀CVD฀ rehospitalization฀ after฀ 90฀ days฀ of฀
prior฀CVD฀hospitalization.
Clinical measurements and missing data
Objective clinical measurements were used as predictors in the 
model, including BMI and blood pressure [systolic blood pressure 
(SBP) and diastolic blood pressure (DBP)] and the metabolic vari-
ables฀glycated฀hemoglobin฀(HbA1c)฀and฀lipid฀proile.฀We฀also฀in-
cluded demographic characteristics (age and gender) and whether 
the patient was on lipid-lowering treatment. Patients with diabetes 
were invited to have their blood pressure and metabolic variables 
measured at least once a year after the diagnosis of diabetes, and 
the most recent was taken before 1 April 2009 (a minimum of 50 
days before the first admission). Diabetes duration was not univer-
sally recorded, and hence was not usefully available for analysis. 
Diabetes therapy was not included in the dataset. The TC/HDL 
was defined as the ratio of total cholesterol to HDL cholesterol.
The฀ ECF฀ cohort฀ had฀missing฀ information฀ on฀ BMI฀ (3.17%),฀
SBP (9.95%), DBP (9.95%), total cholesterol (12.35%), HDL 
(14.56%),฀ and฀LDL฀(16.27%).฀We฀used฀multiple฀ imputation฀
to฀replace฀missing฀values฀by฀using฀a฀chained฀equation฀approach฀
based฀on฀all฀candidate฀predictors฀and฀outcomes.฀We฀created฀16฀
imputed datasets for missing variables that were then combined 
across all datasets by using Rubin’s rule to obtain final model esti-
mates. Limited information was missing (<1%) in RAPSID, and 
the complete dataset was used in our analysis.
Ethical approval
The derivation cohort work had approval from the Cam-
bridgeshire research ethics committee as part of a wider service 
evaluation.฀Ethics฀approval฀for฀the฀validation฀cohort฀was฀received฀
from฀the฀Cambridgeshire฀REC2฀Committee฀(10/H0308/72),฀and฀
signed consent included agreement for access to hospital data.
Statistical analysis
We฀used฀ “incidence฀occurrence฀of฀CVD฀hospitalization฀ after฀
the first 90 days since the start of follow-up” and the “incident oc-
currence฀of฀CVD฀rehospitalization”฀as฀binary฀outcome฀measures.฀
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A multivariable logistic regression model was used to explore the 
prospective association between TC/HDL and risks of CVD hospi-
talization฀ and฀ rehospitalization฀ with฀ adjustment฀ of฀ covariables฀
presented in Table 1. The adjusted incidence rates ratio was esti-
mated as C exp( )ˆadjusted IRR , with estimated regression coeffi-
cients () from the multivariable logistic regression model.
The dose-response relationships between TC/HDL and risks 
of฀CVD฀hospitalization฀and฀rehospitalization฀were฀estimated฀us-
ing a linear model, a natural cubic spline model with three 
equally฀ spaced฀ knots฀ determined฀ from฀ the฀ levels฀ of฀ TC/HDL฀
measures,฀and฀a฀quadratic฀spline฀model.฀The฀natural฀cubic฀spline฀
model was chosen as the best-fit model for the relationship curve 
by its minimum Akaike information criterion (AIC) compared 
with฀the฀linear฀model฀or฀quadratic฀spline฀model.฀The฀linear฀test฀
was used in the natural cubic spline model to test the linearity of 
the relationship. The break-point test11 was carried out to target 
the฀potential฀ thresholds฀(P5–P95฀of฀TC/HDL฀measures)฀by฀ in-
corporating the piecewise term into the cubic spline model. The 
threshold with a significant break in the regression coefficients, 
and achieving the minimum AIC was chosen as the final thresh-
old. The 95% CI of the threshold was obtained from 1,000 boot-
strap samples. As the most important confounder, the role of the 
lipid-lowering agents in the association between TC/HDL and 
risks฀of฀CVD฀hospitalization฀and฀rehospitalization฀was฀also฀pre-
sented. In the first sensitivity analyses, all analyses were carried 
out in the continuous-measurement data-rich range (covering > 
95% people). In the second analysis, all analyses were carried out 
in men and women separately.
RESULTS
Study participants
In฀ the฀ ECF฀ cohort,฀ we฀ analyzed฀ information฀ on฀ 4,704฀
T2D฀patients฀with฀588฀CVD฀hospitalizations฀within฀2฀years฀
and฀ 316฀ rehospitalizations฀ after฀ 90฀ days฀ since฀ a฀ prior฀
CVD฀hospitalization.฀Our฀RAPSID฀cohort฀had฀information฀ 
on฀1,121฀T2D฀patients฀with฀183฀CVD฀hospitalizations฀and฀
78฀rehospitalizations.฀Table 1฀summarizes฀the฀basic฀char-
acteristics and potential predictors of the study popula-
tion at baseline. Patients with T2D in both cohorts had 
similar age, gender, blood pressure, and total cholesterol. 
Patients in the RAPSID cohort had a higher level of HDL, 
LDL,฀and฀HbA1c.฀Compared฀with฀the฀ECF฀cohort,฀those฀
in the RAPSID cohort were more likely to be prescribed 
lipid-lowering฀medicine฀and฀had฀more฀CVD฀hospitalization฀
and฀rehospitalization.
Dose-response relationships between TC/HDL and CVD 
hospitalization and rehospitalization
In฀ both฀ the฀ ECF฀ and฀ RAPSID฀ cohorts,฀ nonlinear฀ 
(“J-shape”) relationships were found between TC/HDL and 
risks฀of฀CVD฀hospitalization฀(both฀P values for linearity test 
<฀0.0001)฀and฀rehospitalization฀(both฀P values for linearity 
test < 0.0001). Relationship curves were derived from the 
natural cubic spline models with adjustment of covariates 
in Fig. 1. Similar dose-response relationships were revealed 
in the sensitivity analyses modeling the associations within 
the฀data-rich฀range฀(5th–95th฀percentile฀of฀the฀above฀mea-
surements) as shown in supplemental Fig. S1 for both the 
ECF฀ and฀ RAPSID฀ cohorts.฀ In฀ another฀ sensitivity฀ analysis฀
modeling the associations by gender, similar dose-response 
relationships were identified in men and women for both 
the฀ECF฀and฀RAPSID฀cohorts฀(supplemental฀Fig.฀S2).
For฀ both฀ CVD฀ hospitalization฀ and฀ rehospitalization,฀ a฀
TC/HDL฀below฀2.8฀(95%฀CI:฀2.6–3.0)฀was฀estimated฀to฀be฀
associated฀with฀the฀lowest฀risk฀of฀CVD฀hospitalization฀and฀
rehospitalization฀ both฀ in฀ ECF฀ and฀ RAPSID฀ cohorts,฀ as฀
tested by linear threshold models. The thresholds were the 
same among men and women. Table 2 shows the CVD hos-
pitalization฀ and฀ rehospitalization฀ rates฀ below฀ and฀ above฀
the฀threshold.฀In฀the฀ECF฀cohort,฀the฀CVD฀hospitalization฀
rates below and above the threshold were 9.8% (of 2,211 
participants) and 14.9% (of 2,493 participants), respec-
tively, and in the RAPSID cohort, 14.5% (of 269 patients) 
and 16.9% (of 852 patients), respectively. Similarly, CVD 
rehospitalization฀rates฀below฀and฀above฀the฀threshold฀were฀
4.1%฀and฀9.0%฀in฀the฀ECF฀cohort฀and฀6.6%฀and฀7.2%฀in฀
the RAPSID cohort. Table 2 also shows that the risks of 
CVD฀hospitalization฀and฀rehospitalization฀increase฀signii-
cantly with a 1 unit increase of TC/HDL above the TC/
HDL฀threshold฀(2.8)฀in฀both฀the฀ECF฀and฀RAPSID฀cohorts:฀
adjusted incidence rates ratio (IRR) per TC/HDL unit for 
CVD฀hospitalization฀1.39฀(95%฀CI:฀1.37–1.41,฀P < 0.0001) 
in฀ECF฀and฀1.18฀(1.15–1.22,฀P฀=฀0.012)฀in฀RAPSID;฀adjusted฀
IRR฀for฀CVD฀rehospitalization฀1.20฀(1.17–1.23,฀P < 0.0001) 
in฀ECF฀ and฀ 1.17฀ (1.13–1.21,฀P = 0.040) in RAPSID. The 
risks฀of฀CVD฀hospitalization฀and฀rehospitalization฀did฀not฀
TABLE 1.฀ Baseline฀characteristics฀of฀study฀populations฀in฀the฀ECF฀and฀RAPSID฀cohorts
ECF฀cohort RAPSID cohort
n 4,704 1,121
CVD฀hospitalization,฀n฀(%) 588 (12.5) 183 (16.3)
CVD฀rehospitalization,฀n฀(%) 316฀(6.7) 78฀(7.0)
Female, n (%) 1,919 (40.8) 444 (39.6)
Lipid-lowering treatment, n (%) 3,342฀(71.4) 731฀(65.2)
Age, years 65.0฀(56.0฀–77.0) 65.8฀(60.0–72.1)
BMI, kg/m2 30.8฀(26.2–34.3) 32.3฀(28.0–35.4)
SBP, mmHg 135.0฀(125.0–143.0) 139.3฀(128.3–151.0)
DBP, mmHg 76.5฀(70.0–82.0) 75.5฀(69.0–82.3)
HbA1c, mmol/mol 61.6฀(49.7–70.5) 56.5฀(48.0–63.0)
Total cholesterol, mmol/l 4.3฀(3.6–5.0) 4.2฀(3.6–5.0)
HDL, mmol/l 1.3฀(1.0฀–1.6) 1.2฀(1.0–1.4)
LDL, mmol/l 2.5฀(1.7฀–3.3) 2.4฀(1.5–2.7)
TC/HDL 3.1฀(2.6฀–4.5) 3.7฀(2.8–4.4)
Age, gender, SBP, DBP, BMI, HbA1c, LDL cholesterol, and lipid-lowering treatment were adjusted. Categorical 
variable฀is฀presented฀as฀n฀(%).฀Continuous฀variable฀is฀presented฀as฀median฀(interquartile฀rage).
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increase significantly with a 1 unit increase of TC/HDL be-
low฀the฀TC/HDL฀threshold฀(2.8)฀in฀either฀the฀ECF฀or฀RAP-
SID฀cohorts:฀adjusted฀IRR฀for฀CVD฀hospitalization฀was฀1.05฀
(0.97–1.14,฀P฀=฀0.062)฀in฀ECF฀and฀1.00฀(0.85–1.19,฀P = 0.595) 
in฀RAPSID;฀adjusted฀IRR฀for฀CVD฀rehospitalization฀was฀1.04฀
(0.94–1.17,฀P฀=฀0.272)฀in฀ECF฀and฀0.90฀(0.72–1.12,฀P = 0.385) 
in RAPSID. Findings were similar in men and women (sup-
plemental table S1).
Lipid-lowering agent was not a significant entrant into 
the model, and the distribution of the TC/HDL ratio 
was not significantly different between patients with and 
without lipid-lowering agents in each cohort (adjusted IRR 
for฀CVD฀hospitalization:฀1.01฀(0.96–1.06)฀and฀0.99฀(0.89–
1.09)฀ for฀ECF฀and฀RAPSID฀cohorts,฀ respectively;฀ IRR฀ for฀
rehospitalization:฀ 0.99฀ (0.93–1.05)฀ and฀ 1.00฀ (0.98–1.01)฀
for฀ECF฀and฀RAPSID฀cohorts,฀ respectively).฀ Similar฀ind-
ings were found in men and women: IRR for CVD hospital-
ization:฀1.01฀(0.90–1.14)฀and฀1.01฀(0.97–1.04)฀in฀men฀and฀
1.00฀(0.99–1.01)฀and฀0.99฀(0.97–1.02)฀ in฀women฀for฀ECF฀
and฀RAPSID฀cohorts,฀respectively;฀IRR฀for฀CVD฀rehospital-
ization:฀1.00฀(0.98–1.01)฀and฀1.00฀(0.96–1.05)฀in฀men฀and฀
1.00฀(0.99–1.02)฀and฀0.98฀(0.94–1.02)฀ in฀women฀for฀ECF฀
and RAPSID cohorts, respectively.
DISCUSSION
Our study was undertaken to relate TC/HDL to the risks of 
CVD฀hospitalization฀and฀rehospitalization฀in฀two฀independent฀
Fig. 1.฀ Adjusted฀dose-response฀associations฀between฀TC/HDL฀cholesterol฀ratio฀and฀adjusted฀incidence฀rates฀ratios฀for฀CVD฀hospitalization฀
and฀rehospitalization฀in฀the฀ECF฀and฀RAPSID฀cohorts฀
TC/HDL predict CVD (re)hospitalization in diabetes 1749
cohorts฀of฀patients฀with฀T2D.฀We฀focused฀our฀investigation฀
on the dose-response relationships assessing the evidence 
for nonlinear and particular in the existence of a thresh-
old. In all our analyses, we found evidence that the associa-
tions are nonlinear. Threshold analysis provided evidence 
of฀ a฀ TC/HDL฀ threshold:฀ 2.8฀ (2.6–3.0).฀ The฀ signiicantly฀
higher risks of CVD admissions and readmissions were 
found above 2.8 of TC/HDL.
Heart UK has recommended that a TC/HDL above 6 be 
regarded as a major risk factor for heart disease (14). How-
ever, Diabetes UK recommends a lower treatment goal of 
below 4 in diabetes patients (15). There are some other 
studies that set the TC/HDL ratio target below 4 for pa-
tients with T2D (16). However, based on our findings, com-
paring patients with TC/HDL at 2.8, for people with TC/
HDL at 4.0, there was 55.2% and 24.0% increased risks of 
CVD฀ hospitalization฀ within฀ 2฀ years฀ and฀ rehospitalization฀
after฀90฀days฀of฀prior฀CVD฀hospitalization,฀respectively.
Our results extend previous findings, suggesting a 
“J-shaped” nonlinear association between TC/HDL and risks 
of฀both฀CVD฀hospitalization฀and฀rehospitalization฀among฀
people with T2D. The existence of a nonlinear relationship 
between TC/HDL and CVD outcomes has not been investi-
gated before. In most previous studies, the association be-
tween฀TC/HDL฀and฀CVD฀outcomes฀were฀analyzed฀by฀1฀unit฀
or 1 SD increase, assuming linearity (consistent slope), which 
may have led to an underestimate of the risk of CVD events 
(17,฀18).฀In฀other฀studies,฀the฀TC/HDL฀has฀been฀categorized฀
into several groups based on percentiles, with the association 
analyzed฀by฀increases฀by฀1฀unit฀or฀1฀SD.฀The฀different฀slopes฀
of association between TC/HDL and CVD outcomes have 
been presented over categories of TC/HDL, which also actu-
ally indicated that the association was nonlinear (19, 20). 
However, a threshold could not be identified by this strategy. 
Moreover,฀this฀strategy฀of฀categorized฀exposure฀is฀not฀recom-
mended, as it leads to the loss of statistical power and the in-
troduction of residual confounders. Therefore, in our study, 
TC/HDL was treated as a continuous variable, and nonlinear 
models were examined in an independent cohort study as 
the best-fitted model. The TC/HDL threshold of 2.8 was 
consistently identified in both cohorts for both genders and 
for฀both฀CVD฀hospitalization฀and฀rehospitalization.
Previous studies have not focused on CVD as both a ma-
jor cause and cost for hospital admission among patients 
with diabetes. Understanding the potential risk of CVD 
hospitalization฀in฀the฀next฀year฀and฀the฀risk฀of฀a฀new฀epi-
sode฀(within฀90฀days)฀of฀a฀CVD฀event฀(rehospitalization)฀
could be helpful for clinicians to facilitate tailored, more 
intensive management to those with high TC/HDL and to 
reduce฀hospitalization฀inpatient฀costs.
Our฀study฀has฀several฀advantages.฀We฀examined฀associa-
tions฀between฀TC/HDL฀and฀CVD฀hospitalization฀and฀re-
hospitalization฀ in฀ two฀ independent฀ prospective฀ cohorts,฀
which suggests that the findings in this study are reliable. 
The variables used in this study are from routinely recorded 
demographic and clinical measurements in primary care 
settings, which suggests that the findings in this study could 
increase the introduction of lipid-lowering treatment for 
people with T2D in clinical practice within countries that 
have฀ routine฀ recorded฀ data฀ accessible.฀ We฀ acknowledge฀
that our study does not take into account diabetes dura-
tion, antidiabetes treatments, prior history of CVD, other 
diabetes complications (e.g., renal failure), lifestyle risk 
factors (like smoking), and other comorbidities due to lim-
itations in the original data, but we feel that the clinical 
measurements included in our study could be proxies for 
missing predictors. A small minority of CVD events would 
have resulted in death, but data relating to mortality were 
not accessible due to linkage limitations. Based on the cur-
rent study, the threshold is the same for the men and 
women. In this study, the event numbers are not enough 
for us to repeat the analyses by gender, which will be tested 
in future studies.
As far as we are aware, our study is the first study to inves-
tigate the associations between TC/HDL and the 2 year 
risk฀of฀CVD฀hospitalization฀and฀rehospitalization฀within฀
90฀days฀of฀a฀previous฀hospitalization฀in฀two฀independent฀pro-
spective cohort studies. Our study has two important impli-
cations for clinical practice. First, the relationship between 
TC/HDL and CVD outcomes are nonlinear, which sug-
gests that the risk of CVD outcomes might be substantially 
underestimated by previous studies in which linear shapes 
were assumed. Second, our finding suggests that T2D pa-
tients with a TC/HDL ratio at 2.8 have the lowest risk of 
CVD outcomes, much lower than the 4.0 accepted in previ-
ous฀ clinical฀ guidelines.฀ This฀ suggests฀ that฀ 33%฀ (ECF฀ co-
hort) to 44% (RAPSID cohort) of patients whose TC/HDL 
are฀between฀2.8฀and฀4.0฀[similar฀by฀gender:฀32%฀(ECF)฀to฀
TABLE 2.฀ Adjusted฀IRRs฀for฀CVD฀hospitalization฀and฀rehospitalization฀by฀1฀unit฀increase฀in฀TC/HDL฀ratio฀in฀groups฀classiied฀by฀TC/HDL฀
threshold฀(2.8)฀in฀the฀ECF฀and฀RAPSID฀cohorts
ECF฀cohort RAPSID cohort
TC/HDL ratio  2.8  
[n฀=฀2,211฀(47.0%)] P
TC/HDL ratio > 2.8  
[n = 2,493 (53.0%)] P
TC/HDL ratio  2.8  
[n = 269 (24.0%)] P
TC/HDL ratio > 2.8  
[n฀=฀852฀(76.0%)] P
CVD฀hospitalization
฀ Hospitalization,฀n฀(%) 216 (9.8) — 372฀(14.9) — 39 (14.5) 144 (16.9)
 Adjusted IRRa 1.09฀(1.00–1.19) 0.020 1.55฀(1.53–1.57) <0.0001 1.05฀(0.86–1.27) 0.890 1.24฀(1.20–1.27) 0.016
 Adjusted IRRb 1.05฀(0.97–1.14) 0.062 1.39฀(1.37–1.41) <0.0001 1.00฀(0.85–1.19) 0.595 1.18฀(1.15–1.22) 0.012
CVD฀rehospitalization
฀ Rehospitalization,฀n฀(%) 91 (4.1) — 225 (9.0) — 18 (6.6) 60฀(7.2)
 Adjusted IRRa 1.08฀(0.95–1.22) 0.390 1.46฀(1.43–1.49) <0.0001 1.07฀(0.98–1.18) 0.932 1.30฀(1.24–1.36) 0.001
 Adjusted IRRb 1.04฀(0.94–1.17) 0.272 1.20฀(1.17–1.23) <0.0001 0.90฀(0.72–1.12) 0.385 1.17฀(1.13–1.21) 0.040
a Indicates age and gender were adjusted. 
b Indicates that age, gender, SBP, DBP, BMI, HbA1c, LDL cholesterol, and lipid-lowering treatment were adjusted.
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45%฀(RAPSID)฀in฀men;฀34%฀(ECF)฀to฀46%฀(RAPSID)฀in฀
women] may need more intensive lipid-lowering treat-
ment, introduced at an earlier stage, to achieve this new 
optimal฀control฀ target.฀Studies฀are฀ required฀ to฀assess฀ the฀
effectiveness and cost-effectiveness of these strategies.
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